Key points are not available for this paper at this time.
The novel therapeutic DNA vaccine VB10.16 was well tolerated and showed promising evidence of efficacy and strong HPV16-specific T-cell responses in subjects with high-grade CIN.
Hillemanns et al. (Wed,) studied this question.